{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:13:46Z","timestamp":1789398826101,"version":"build-2803163510"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,4,7]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the similarity in symptoms between primary Sjogren\u2019s syndrome (SjS) and non-SjS sicca syndrome (sicca), we sought to characterise clinical and proteomic predictors of symptoms in both groups in order to better understand disease mechanisms and help guide development of immunomodulatory treatments. These have not, to date, unequivocally improved symptoms in SjS clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum proteomics was performed using O-link inflammation and cardiovascular II panels. SjS (n=53) fulfilled 2016 ACR\/European Alliance of Associations for Rheumatology (EULAR) criteria whereas sicca (n=60) were anti-Ro negative, displayed objective or subjective dryness, and either had a negative salivary gland biopsy or, in the absence of a biopsy, it was considered that a biopsy result would not change classification status. Linear regression analysis was performed to identify the key predictors of symptoms. Cluster analysis was completed using protein expression values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>EULAR-Sj\u00f6gren\u2019s-Syndrome-Patient-Reported-Index (ESSPRI), EuroQoL-5 Dimension utility values, and anxiety and depression did not differ between SjS and sicca. Correlations between body mass index (BMI) and ESSPRI were found in sicca and to a lesser extent in SjS. Twenty proteins positively associated with symptoms in sicca but none in SjS. We identified two proteomically defined subgroups in sicca and two in SjS that differed in symptom burden. Within hierarchical clustering of the SjS and sicca pool, the highest symptom burden groups were the least distinct. Levels of adrenomedullin (ADM), soluble CD40 (CD40) and spondin 2 (SPON2) together explained 51% of symptom variability in sicca. ADM was strongly correlated with ESSPRI (spearman\u2019s r=0.62; p&lt;0.0001), even in a multivariate model corrected for BMI, age, objective dryness, depression and anxiety scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Obesity-related metabolic factors may regulate symptoms in sicca. Further work should explore non-inflammatory drivers of high symptom burden in SjS to improve clinical trial outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002119","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T11:46:10Z","timestamp":1652960770000},"page":"e002119","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Sj\u00f6gren\u2019s and non-Sj\u00f6gren\u2019s sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7683-4568","authenticated-orcid":false,"given":"Valentina","family":"Pucino","sequence":"first","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D","family":"Turner","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Nayar","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kollert","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaeha","family":"Rauz","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine, Birmingham Dental Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Higham","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine, Birmingham Dental Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Poveda-Gallego","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"Department of Oral Medicine, Birmingham Dental Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Bowman","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"Candel Therapeutics, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-549X","authenticated-orcid":false,"given":"Benjamin A","family":"Fisher","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"},{"name":"National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"2025090312191180000_8.1.e002119.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743"},{"key":"2025090312191180000_8.1.e002119.2","article-title":"Health-related quality of life and costs in Sj\u00f6gren\u2019s syndrome","volume":"15","author":"Miyamoto","year":"2019","journal-title":"Rheumatology"},{"key":"2025090312191180000_8.1.e002119.3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sj\u00f6gren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312191180000_8.1.e002119.4","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312191180000_8.1.e002119.5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025090312191180000_8.1.e002119.6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"2025090312191180000_8.1.e002119.7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000282"},{"key":"2025090312191180000_8.1.e002119.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2018.11.032"},{"key":"2025090312191180000_8.1.e002119.9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1400121","article-title":"Distinct plasma immune signatures in ME\/CFS are present early in the course of illness","volume":"1","author":"Hornig","year":"2015","journal-title":"Sci Adv"},{"key":"2025090312191180000_8.1.e002119.10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1007\/s10067-018-4159-2","article-title":"Serological lymphocytic activity and patient-reported outcomes in Sj\u00f6gren's syndrome","volume":"37","author":"J\u00fclich","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090312191180000_8.1.e002119.11","doi-asserted-by":"publisher","DOI":"10.1172\/jci132185"},{"key":"2025090312191180000_8.1.e002119.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1607571113"},{"key":"2025090312191180000_8.1.e002119.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.416"},{"key":"2025090312191180000_8.1.e002119.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg226"},{"key":"2025090312191180000_8.1.e002119.15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000495"},{"key":"2025090312191180000_8.1.e002119.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket270"},{"key":"2025090312191180000_8.1.e002119.17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jbspin.2015.10.005","article-title":"Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sj\u00f6gren's syndrome","volume":"83","author":"Milin","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090312191180000_8.1.e002119.18","doi-asserted-by":"crossref","unstructured":"Tashbayev B , Garen T , Palm \u00d8. , et al . Patients with non-Sj\u00f6gren\u2019s sicca report poorer general and oral health-related quality of life than patients with Sj\u00f6gren\u2019s syndrome: a cross-sectional study. Sci Rep 2020;10.doi:10.1038\/s41598-020-59078-0","DOI":"10.1038\/s41598-020-59078-0"},{"key":"2025090312191180000_8.1.e002119.19","first-page":"216","article-title":"Mediterranean diet and risk of Sj\u00f6gren's syndrome","volume":"38 Suppl 126","author":"Machowicz","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312191180000_8.1.e002119.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210571"},{"key":"2025090312191180000_8.1.e002119.21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bdq.2015.04.002","article-title":"Proximity assays for sensitive quantification of proteins","volume":"4","author":"Greenwood","year":"2015","journal-title":"Biomol Detect Quantif"},{"key":"2025090312191180000_8.1.e002119.22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/bioinformatics\/btz704","article-title":"Spectrum: fast density-aware spectral clustering for single and multi-omic data","volume":"36","author":"John","year":"2020","journal-title":"Bioinformatics"},{"key":"2025090312191180000_8.1.e002119.23","unstructured":"Kolde R . pheatmap: pretty Heatmaps. R package version 1.0.12, 2019."},{"key":"2025090312191180000_8.1.e002119.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206008"},{"key":"2025090312191180000_8.1.e002119.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00576","article-title":"Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases)","volume":"5","author":"Gremese","year":"2014","journal-title":"Front Immunol"},{"key":"2025090312191180000_8.1.e002119.26","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025090312191180000_8.1.e002119.27","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.4103\/1673-5374.272567","article-title":"Adrenomedullin: an important participant in neurological diseases","volume":"15","author":"Li","year":"2020","journal-title":"Neural Regen Res"},{"key":"2025090312191180000_8.1.e002119.28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neulet.2013.07.055","article-title":"Intrathecal adrenomedullin modulates acute inflammatory pain in the rat formalin test","volume":"552","author":"Sugimoto","year":"2013","journal-title":"Neurosci Lett"},{"key":"2025090312191180000_8.1.e002119.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.07.015"},{"key":"2025090312191180000_8.1.e002119.30","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1852"},{"key":"2025090312191180000_8.1.e002119.31","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/S2665-9913(20)30038-2","article-title":"Rationale for CD40 pathway blockade in autoimmune rheumatic disorders","volume":"2","author":"Pucino","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090312191180000_8.1.e002119.32","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090312191180000_8.1.e002119.33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/rheumatology\/kez255","article-title":"Cxcl13 as biomarker for histological involvement in Sj\u00f6gren's syndrome","volume":"59","author":"Colafrancesco","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312191180000_8.1.e002119.34","unstructured":"Bost PMX , Bondet V , Llibre A , et al . Systems Biology in 874 Patients with Primary Sj\u00f6gren\u2019s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA [abstract]. Arthritis Rheumatol 2019;71."}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:19:22Z","timestamp":1756927162000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,5,19]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/rmdopen-2021-002119"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002119","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}